key: cord-0687757-3e95r7hz
authors: Pasupuleti, Raghavendra Rao; Tsai, Pei-Chien; Ponnusamy, Vinoth Kumar; Pugazhendhi, Arivalagan
title: Rapid Determination of Remdesivir (SARS-CoV-2 Drug) in Human Plasma for Therapeutic Drug Monitoring in COVID-19-Patients
date: 2020-12-25
journal: Process Biochem
DOI: 10.1016/j.procbio.2020.12.014
sha: db5f7b9bf775d6d7ae488b2dbdd1334a932343b4
doc_id: 687757
cord_uid: 3e95r7hz

To tackle the harmful consequences of the widespread COVID-19 pandemic, a broad-spectrum anti-viral drug remdesivir (RDV) has gained the utmost attention recently due to its promising application in treating COVID-19 patients. However, a fast and sensitive analytical methodology is important to monitor RDV drug profile in human plasma for pharmacokinetics (PK) and therapeutic drug monitoring (TDM). In this study, we demonstrate an improved vortex-assisted salt-induced liquid-liquid microextraction (VA-SI-LLME) technique coupled with UHPLC-PDA and UHPLC-MS/MS for rapid determination of RDV in human plasma. This technique involves simple one-step protein precipitation with hydrochloric acid and subsequent extraction with acetonitrile for analysis. Under the optimal VA-SI-LLME conditions (500 μL of acetonitrile with 2.5 g ammonium sulfate under 2 min vortex extraction), method validation results indicated an excellent correlation coefficient of 0.9969 for UHPLC-PDA (monitored at 254 nm) and 0.9990 for UHPLC-MS/MS (monitored at electrospray ionization with + ion mode transitions of m/z 603.1→m/z 402.20 and m/z 603.1→ m/z 199.90). The detection and quantification limits were 1.5 and 5 ng/mL for UHPLC/PDA, and 0.3 and 1 ng/mL for UHPLC-MS/MS, respectively. The developed method showed excellent extraction recoveries between 90.79 to 116.74 % and 85.68 to 101.34 % with intraday and interday precision ≤ 9.59 for both methods. These results proved that the developed method is a simple, fast, and sensitive analytical method that can be applied as a standard analytical tool for PK and TDM studies of RDV in clinical trials during the current worldwide outbreak.

RDV is a small molecule and, acting as a therapeutic agent against the Ebola virus in rhesus monkeys, which has been developed by the Gilead Sciences biopharmaceutical company [15] . The anti-viral activity of RDV has been proven for SARS and MERS RNA viruses [16] . Based on the observed activity of RDV towards SARS-CoV-2 clinical trials have been initiated, and the recent studies on RDV showed in vitro inhibition of SARS-CoV-2 [17, 18] . The replication process of COVID-19 virus can be reduced on drug administration by inhibiting the RNA-dependent polymerase, thus, proving the efficacy of RDV [19] [20] [21] [22] . The European Medicines Agency (EMA) has not yet approved the COVID-19 treatment with RDV, but on the other hand United States Food and Drug Administration (US FDA) has marked its authentication and has been several ongoing studies and trials on the patients suffering from COVID-19 [21] . For targeting the SARS-CoV-2 in the COVID-19 patients, 200 mg dosage of RDV was prescribed on the first day, followed by 100 mg dose for the next nine days through route IV administration was proposed by Gilead. The RDV pharmacodynamics (PD), pharmacokinetic (PK), and therapeutic drug monitoring (TDM) studies are essential in the emergency COVID-19 pandemic situation. Consequently, researchers aimed to develop analytical methods to monitor the RDV for the above applications.

To date, only a few studies have been reported for the quantification of RDV in plasma [23] [24] [25] [26] [27] ; however, these methods are laborious and time-consuming. Therefore, it is crucial to develop a simple, fast, sensitive, and accurate method for the monitoring of RDV in human plasma samples for PK and TDM applications during COVID-19 treatment. The main objective of this work is to develop a sensitive and robust analytical approach with minimal sample preparation process that can be applied as a routine tool for monitoring the dose of RDV in human plasma for the PK and TDM studies. For the first time, an improved vortex-assisted salt-J o u r n a l P r e -p r o o f 6 induced liquid-liquid microextraction (VA-SI-LLME) technique coupled with ultra-highpressure liquid chromatography with photodiode array (UHPLC-PDA) and tandem mass spectrometric technique (UHPLC-MS/MS) was developed for rapid quantification of RDV in human plasma. Several factors affecting the VA-SI-LLME method were carefully examined, including the type of extraction solvent, solvent volume, extraction time, salt type, and amount, and also analytical method was validated based on FDA guidelines, which can be applied for the routine monitoring of RDV in human plasma for PK and TDM studies.

Remdesivir (RDV) (99% purity) was obtained from MedKoo Biosciences, Inc.

Morrisville, USA. RDV standard was stored in a dark place at −20 °C refrigerator to avoid degradation. LCMS grade solvent acetonitrile (ACN) and methanol were acquired from J.T.

Baker Chemical Co. (Phillipsburg, NJ, United States). HPLC grade isopropanol and acetone were obtained from ECHO Chemicals CO., LTD (Taiwan). Dimethyl-sulfoxide (DMSO), tetrahydrofuran, ammonium sulfate ((NH4)2SO4), sodium chloride (NaCl), sodium sulfate (Na2SO4), magnesium sulfate (MgSO4), were bought from Xilong Scientific Co. Ltd (Shanghai, China). Hydrochloric acid (HCl 37%) and formic acid were acquired from Fisher Chemical (Leicestershire, UK). Ultrapure water utilized in this work was prepared using an Uniss Pure water system (from Taiwan). Drug-free blank human plasma samples were purchased from Merck Chemicals and used for method development, validation, and recovery studies.

J o u r n a l P r e -p r o o f

RDV stock solution (5000 µg/mL) was prepared by dissolving RDV drug powder using the mixture of DMSO:MeOH (30:70 v/v). The chemical structure of RDV is displayed in Fig.1 .

Working standard, calibration standard, and quality control solutions were prepared using methanol by diluting the RDV stock solution. The RDV working standard solutions for calibration and quality controls were prepared using methanol in concentrations of 100, 10, 1, 0.1, 0.01 µg/mL. 1, 2.5, 5, 7.5, 10, 25, 50, 75, 100, 250, 500, 1000, and 5000 ng/mL sample solutions were prepared freshly by spiking calibration standard solutions into the blank human plasma samples for method calibration.

The graphical representation of the VA-SI-LLME process was displayed in Fig. 2 . In the typical VA-SI-LLME extraction procedure, 50 µL of human plasma sample was pipetted into a clean 5 mL glass test tube, and 2.0 mL of 0.1N HCl was added into the sample. The glass tube was then vortexed for 30 sec; subsequently, 2.5 g of (NH4)2SO4 and 500 µL of ACN as an extraction solvent were added into the sample solution. After that, the mixture solution was vortexed for 2 min and centrifuged at 6000 rpm for 5 min by maintaining the centrifuge temperature at 4 °C. After centrifugation, the upper layer (supernatant layer) was collected into a fresh glass tube using a 0.5 mL glass syringe. Then, the extraction solvent was dried under nitrogen by a concentration evaporator. The final residue was re-dissolved using 100 µL of methanol and shifted into an HPLC vial for the analysis.

J o u r n a l P r e -p r o o f

RDV analysis was performed using a Shimadzu UHPLC Nexera-I series 2040C 3D system consisting of a quaternary pump (Tokyo, Japan). An ACE C18 column (150 × 4.6 mm, 3 µm) brought from Advanced Chromatography Technologies Ltd (Aberdeen, Scotland) was utilized for the separation of RDV. The mobile phase A used was 0.05% (v/v) formic acid in ultrapure water, and mobile phase B was 100% ACN with isocratic elution (A: B) 52:48 % with the total analysis time of 10 min. The column flow rate was set at 0.5 mL/min with 35°C as the ideal column temperature, and the injection volume was 5 µL. RDV was monitored at 254 nm absorbance in the PDA detector.

The UHPLC parameters utilized were the same as mentioned in UHPLC-PDA method parameters section 2.4.1. The RDV was also simultaneously monitored using a Shimadzu UHPLC-MS/MS system model LCMS-8045 (Tokyo, Japan) equipped with triple quadrupole with an electrospray ionization (ESI) source. The ESI positive ion mode was used to detect RDV with the scheduled multiple reaction monitoring (MRM) mode by the protonated RDV molecule used as precursor ion. The ESI ion source heating block temperature was set at 300 ºC, DL temperature was set at 250 ºC, the interface temperature was set at 300 ºC, the heating gas flow rate at 10 L/min, the nebulizing gas flow rate at 3 L/ min, and drying gas flow 10 L/min for the 

Various factors affecting the extraction recoveries in the developed VA-SI-LLME procedure, including extraction solvent type, solvent volume, extraction time, salt type, and salt amount, were assessed utilizing RDV standard solutions.

The extraction solvent opting is the core aspect of the equilibrium dependent extractions.

The essential criteria for selecting extraction solvent in the developed VA-SI-LLME are as follows i) maximum extraction ability towards target analytes, ii) the density of the solvent should be lower than water, iii) miscibility with the aqueous phase, iv) solvent must also to possess the efficiency to precipitate proteins in the plasma sample to achieve cleaner extract after extraction. The initial experiment trials were carried out with water-miscible solvents such as acetonitrile (ACN), isopropanol (IPA), tetrahydrofuran (THF), and acetone (ACT) [28] . The results achieved are presented in Fig. 3 . ACN showed maximum extraction recovery for the RDV drug when compared to THF, IPA, and ACT. The reason is that the ACN indicated high extraction efficiency towards RDV is due to its polarity and high miscibility in water, and more efficient in providing the salting-out effect along with higher protein precipitation capacity from human plasma [29] . The other solvents THF, IPA, and ACT, were showed less protein precipitation and low extraction recoveries. Therefore, ACN was utilized as an ideal solvent for extraction and consequent experiments.

The solvent volume is the essential aspect in the liquid phase microextraction techniques because it directly affects the extraction recoveries, and the volume should be adequate to extract all the analytes from the sample. The influence of extraction solvent (ACN) volume on the extraction recoveries of RDV was investigated by examining various ACN volumes, including 0.25, 0.5, 0.75, 1.0, 1.25, and 1.5 mL, and the acquired results were displayed in Fig. 4 . The extraction recovery was increased by an increase in the ACN volume from 0.2 to 0.5 mL, and the maximum extraction recovery was obtained at 0.5 mL of ACN (Fig. 4) . The extraction recovery of RDV almost remained similar when further increasing ACN volume because the collected extract was reconstituted to 100 µL for analysis. Volumes less than 0.5 mL ACN showed significantly less phase separation and not achieved the complete extraction due to the insufficient ACN volume for the extraction of RDV. Therefore, 0.5 mL of ACN was selected as the optimum solvent volume for further investigation.

The distribution of analytes between aqueous and organic phases mainly depends on extraction time; hence extraction time is the main parameter in all the LLME techniques, particularly in this VA-SI-LLME technique. Various studies have reported that vortex agitation enhancing the extraction recoveries of target analytes from aqueous sample solution to the organic extraction phase [30, 31] . In this work, the effect of vortex times were investigated in terms of extraction time, such as 30, 60, 90, 120, 150, and 180 sec. As indicated in 

The addition of salt to the sample solution can increase the ionic strength of the sample solution, thereby reduces the solubility of target analytes in the aqueous solution phase by means of the salting-out effect. Therefore, it leads to the efficient transfer of analytes into the organic extraction phase to achieve maximum preconcentration. Moreover, salt addition into the sample is also to reduce matrix interferences, especially in biological and food samples [32, 33] . In this work, the influence of different kind of salt addition into the sample solution, including ammonium sulfate ((NH4)2SO4), magnesium sulfate (MgSO4), sodium sulfate (Na2SO4), and sodium chloride (NaCl) were examined. The obtained results were shown in Fig. 6 , and the results indicated that ammonium sulfate showed higher extraction recovery than other salts due to the nature of ammonium ions having a higher tendency to salting-out effect than sodium, potassium or magnesium ions. On this basis of results, ammonium sulfate has opted for further studies.

The salt amount is an outmost parameter in the salting-out LLPE techniques. In this work, the effect of salt amount on extraction recoveries was studied from 1 to 3.0 g. The RDV extraction recovery was increased with rising the salt amount from 1 to 2.5g as displayed in Fig.   7 , and this is due to the increase in the salt amount increases the ionic strength in the sample solution which results in the enhances the extractant volume recovery, and also decrease the solubility of RDV drug in the aqueous phase. Further increase in the salt amount higher than 2.5 g showed no effect on extraction recoveries (Fig. 7) . The reason is that increases in salt amount J o u r n a l P r e -p r o o f subsequently increase the sample solution's viscosity, which lowers the transfer of RDV to the organic phase. Therefore, 2.5 g of ammonium sulfate was chosen as the optimum concentration.

The developed VA-SI-LLME technique coupled with UHPLC-PDA and UHPLC-MS/MS method for fast monitoring of RDV in the human plasma sample, was validated under the optimized conditions. The analytical parameters including, linearity, recovery, precision, detection limit (LOD), and lower quantification limit (LLOQ) were evaluated and presented as follows.

The mean retention time of RDV was 5.64 min for spiked human plasma samples in both UHPLC-PDA and UHPLC-MS/MS methods, and the blank and spiked human plasma samples chromatogram were displayed in Fig. 8 and 9 . The column carryover study was investigated by injecting a blank sample after the injection of a higher spiked concertation sample, and results indicated no carryover or interference peaks observed.

The linearity (method calibration curve) study for RDV was carried over the concertation between 5 to 5000 ng/mL for VA-SI-LLME with UHPLC-PDA, and 1 to 5000 ng/mL for UHPLC-MS/MS, respectively. RDV quantitation was carried out by plotting the RDV peak area against the concentration obtained after VA-SI-LLME. The obtained linear equations were J o u r n a l P r e -p r o o f displayed in Table 1 . The correlation coefficients were 0.9969 for UHPLC-PDA, and 0.9990 for UHPLC-MS/MS.

The LLOQ and LOD for the RDV were calculated from the linear equation as follows

Where σ ₌ standard deviation S ₌ slope of analyte obtained from the method calibration curve

The LLOQ was achieved at a lower concentration of 1 ng/mL for UHPLC-MS/MS and 5 ng/mL for UHPLC-PDA. The obtained LOD were 0.3 and 1.5 ng/mL, as showed in Table 1 .

Method precisions and recoveries for quality control samples are displayed in Table 2 .

The recoveries of the RDV were between 90.79 to 116.74 %, with intraday and interday precision ≤ 9.59 for UHPLC-PDA. The recoveries of the RDV were between 85.68 to 101.34 % with intraday and interday precision ≤ 9.39 for UHPLC-MS/MS.

The stability of RDV in human plasma samples were investigated, and the results are showed in Table 3 . Moreover, the RDV stock solution's stability was also examined, and results

showed that it could be stable for at least two weeks if stored adequately at -20 ºC. Although, RDV spiked human plasma samples are found to be unstable at room temperature or 4 ºC if kept for more than 3 days, and it was highly stable at -20 ºC. Therefore, the extraction solvent obtained after VA-SI-LLME from the plasma sample showed good stability until 3 days in HPLC autosampler temperature at 4 ºC, and the RSD was less than 7.54% for 3 days. The achieved analytical results from the method validation indicated good linearity, precision values and showed higher sensitivity. The results obtained from recovery studies indicated that the relative recoveries are in the acceptable range. Hence, the developed VA-SI-LLME coupled UHPLC-PDA and UHLC/MS/MS method is evident to be sensitive, fast, accurate, and reliable for the pharmacokinetics (PK) and therapeutic drug monitoring (TDM) studies of RDV in plasma samples during COVID-19 treatment.

An improved VA-SI-LLME based fast sample preparation technique coupled with UHPLC-PDA and UHPLC-MS/MS methods were developed and validated for the RDV related clinical studies in human plasma samples. This VA-SI-LLME process is simple, fast, low-cost, low-organic solvent consumption, and eco-friendly nature. The analytical method validation studies indicated that the developed technique achieved good extraction recoveries, showed decent linearity, higher sensitivity, and selectivity, and there was no carryover observed. The developed method can be useful for the pharmacokinetics (PK) or therapeutic drug monitoring (TDM) studies of RDV during clinical trials or COVID-19 treatment.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Table 1 

Note: R 2 -correlation coefficients, Lower quantification limit (LLOQ), and limit of detection (LOD) J o u r n a l P r e -p r o o f 33 RSD, relative standard deviation; Quality control samples levels: LLOQ 1 , 5 ng/mL; Low 1 50 ng/mL; LLOQ 2 , 1 ng/mL; Low 2 10 ng/mL; Medium, 500 ng/mL, High, 5000 ng/mL. Note: Low 1 50 ng/mL; Low 2 10 ng/mL; Medium, 500 ng/mL, High, 5000 ng/mL.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

World Health Organization (WHO)

SARS and MERS: recent insights into emerging coronaviruses

Nervous system involvement after infection with COVID-19 and other coronaviruses

A. Pugazhendhi, K. and imaging features of COVID-19

Clinical course and mortality risk of severe COVID-19

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Management of Critically Ill Adults with COVID-19

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Of chloroquine and COVID-19

Covid-19 -The Search for Effective Therapy

Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma

Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Current pharmacological treatments for COVID-19: what's next?

Mechanism of inhibition of ebola virus RNA-dependent RNA polymerase by remdesivir

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus J o u r n a l P r e -p r o o f (2019-nCoV) in vitro

The antiviral compound remdesivir potently inhibits RNAdependent RNA polymerase from Middle East respiratory syndrome coronavirus

Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses, One Heal

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics

Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient

Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: A tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease

Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19, in healthy subjects

Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19

A Promising Antiviral Candidate Drug for the COVID-19 Pandemic: A Mini-Review of Remdesivir

Determination of organic compounds in water using dispersive liquid-liquid microextraction

Salting-out assisted liquid/liquid extraction with acetonitrile: A new high throughput sample preparation technique for good laboratory practice bioanalysis using liquid chromatography-mass spectrometry

Rapid analysis of six phthalate esters in wine by ultrasound-vortex-assisted dispersive liquid-liquid microextraction coupled with gas chromatography-flame ionization detector or gas chromatography-ion trap mass spectrometry

Vortex-assisted extraction combined with dispersive liquid-liquid microextraction for the determination of polycyclic aromatic hydrocarbons in sediment by high performance liquid chromatography

Dynamic Microwave-Assisted Extraction Coupled with Salting-Out Liquid-Liquid Extraction for Determination of Steroid Hormones in Fish Tissues

Rapid screening of haloacetamides in water using saltassisted liquid-liquid extraction coupled injection-port silylation gas chromatographymass spectrometry